Keryx Biopharmaceuticals Sees Significant Growth in Short Interest (KERX)
Keryx Biopharmaceuticals (NASDAQ:KERX) saw a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 19,885,216 shares, an increase of 12.4% from the April 15th total of 17,690,828 shares, Analyst Ratings Net reports. Based on an average daily trading volume, of 2,067,905 shares, the days-to-cover ratio is currently 9.6 days. Approximately 22.7% of the shares of the company are short sold.
A number of research firms have recently commented on KERX. Analysts at MLV & Co
cut their price target on shares of Keryx Biopharmaceuticals from $27.00 to $21.00 in a research note on Monday. They now have a “buy” rating on the stock. Separately, analysts at Mizuho cut their price target on shares of Keryx Biopharmaceuticals from $34.00 to $32.00 in a research note on Friday, May 9th. Finally, analysts at JMP Securities cut their price target on shares of Keryx Biopharmaceuticals from $25.00 to $19.00 in a research note on Friday, May 9th. Eight investment analysts have rated the stock with a buy rating, Keryx Biopharmaceuticals has a consensus rating of “Buy” and a consensus target price of $24.75.
Keryx Biopharmaceuticals (NASDAQ:KERX) opened at 12.92 on Wednesday. Keryx Biopharmaceuticals has a 52 week low of $6.61 and a 52 week high of $17.46. The stock has a 50-day moving average of $14.67 and a 200-day moving average of $14.14. The company’s market cap is $1.175 billion.
Keryx Biopharmaceuticals (NASDAQ:KERX) last released its earnings data on Thursday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.07. The company had revenue of $10.00 million for the quarter, compared to the consensus estimate of $9.91 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. The company’s revenue for the quarter was up 42.9% on a year-over-year basis. Analysts expect that Keryx Biopharmaceuticals will post $-0.72 EPS for the current fiscal year.
Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.